GRP logo
Cost-Effectiveness Analysis alongside Clinical Trials - Good Research Practices II Task Force

Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report

The citation for this report is:
Ramsey SD, Willke RJ, Glick HA, et al.  Cost-effectiveness analysis alongside clinical trials II: An ISPOR good research practices task force report.
Value Health 2015; 18:161-172

Editorial: Clinical Trials Provide Essential Evidence, but Rarely Offer a Vehicle for Cost-Effectiveness Analysis
Mark Sculpher, PhD, Centre for Health Economics, University of York, Heslington, York, UK

Editorial: Merging Regulatory and Reimbursement Needs in Clinical Trials
John C. Cook, PhD, Merck & Co., Inc., Upper Gwynedd, PA, USA

Webinars Icon » Webinar

Leadership Group
Scott D. Ramsey, MD, PhD, (Task Force Co-Chair), Member, Fred Hutchinson Cancer Research Center, Professor, School of Pharmacy School of Medicine
Institute for Public Health Genetics, University of Washington, Seattle, Washington, USA
Richard J. Willke, PhD, (Task Force Co-Chair), Vice President, Outcomes & Evidence Lead, CV/Metabolic, Pain, Urology, Gender Health, Global Health & Value, Pfizer, Inc., New York, NY, USA
Federico Augustovski MD, MSc, PhD, Director, Health Economic Evaluation and Technology Assessment, Institute for
Clinical Effectiveness and Health Policy (IECS);  Professor of Public Health, Universidad de Buenos Aires, Buenos Aires, Argentina
Andrew Briggs,
MSc, DPhil, William R. Lindsay Chair of Health Economics University of Glasgow, Glasgow, Scotland, UK
Wen Chan, PhD, Professor of Health Economics, Center for Pharmacoeconomic Research and Evaluation School of Public Health
Fudan University, Shanghai, China
Henry Glick, PhD
, Professor of Medicine, University of Pennsylvania, Division of Internal Medicine, Philadelphia, PA, USA
Bengt Jonsson, PhD, Professor Emeritus of Health Economics, Stockholm School of Economics, Stockholm, Sweden
Shelby D. Reed, PhD, RPh, Professor in Medicine, Duke Clinical Research Institute, Durham, NC, USA
Sean Sullivan, PhD, Professor and Dean, School of Pharmacy, University of Washington, Seattle, WA, USA
Andrew Willan, MSc, PhD, Senior Scientist at SickKids Research Institute, Professor, Biostatistics, Dalla Lana School of Public Health
University of Toronto, Toronto, Ontario, Canada

Reference:  2005 Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report

Final Report 
The task force sent out drafts for review twice during the development process and received verbal comments on work to date during an ISPOR Forum.  All comments, many of which were substantive, were read by the task force and addressed as appropriate. A list of reviewers is included on the comments page. Participation as a reviewer by ISPOR members contributes to the high quality, expert consensus nature of these scientific guidance reports.

ISPOR Good Practices For Outcomes Research Index